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Objective: To determine if the ﬁxed-dose perindopril/indapamide combination (Per/Ind) 
normalizes blood pressure (BP) in the same fraction of hypertensive patients when treated in 
everyday practice or in controlled trials.
Methods: In this prospective trial, 17 938 hypertensive patients were treated with Per 2 mg/Ind 
0.625 mg for 3–6 months. In Group 1 Per/Ind was initiated in newly diagnosed patients (n = 7032); 
in Group 2 Per/Ind replaced previous therapy in patients already treated but having either their BP 
still uncontrolled or experiencing side-effects (n = 7423); in Group 3 Per/Ind was added to previous 
treatment in patients with persistently high BP (n = 3483). BP was considered normalized when ≤ 
140/90 mm Hg. A multivariate analysis for predictors of BP normalization was performed. 
Results: Subjects were on average 62 years old and had a baseline BP of 162.3/93.6 mm Hg. 
After treatment with Per/Ind, BP normalization was reached in 69.6% of patients in the Initia-
tion group, 67.5% in the Replacement Group, and 67.4% in the Add-on Group (where patients 
were more frequently at risk, diabetic, or with target organ damage). Mean decreases in systolic 
BP of 22.8 mm Hg and in diastolic BP of 12.4 mm Hg were recorded.
Conclusions: This trial was established to reﬂect everyday clinical practice, and a treatment 
strategy based on the Per/Ind combination, administered as initial, replacement, or add-on 
therapy, led to normalization rates that were superior to those observed in Europe in routine 
practice. These results support recent hypertension guidelines which encourage the use of 
combination therapy in the management of arterial hypertension.
Keywords: perindopril, indapamide, blood pressure normalization, risk factors, combination 
therapy.
Introduction
Cardiovascular complications may, to a large extent, be prevented in hypertensive 
patients by lowering blood pressure (BP). International recommendations currently 
stress the importance of an effective control of not only diastolic BP (DBP), but also 
systolic BP (SBP). This is because it is now well recognized that SBP better reﬂects 
cardiovascular risk than DBP. This is especially true in patients older than 50 years 
(Franklin et al 2001).
Despite major efforts directed worldwide to control hypertension, BP normalization 
rates (SBP/DBP <140/90 mm Hg) in treated patients remain low, achieving hardly 30% 
in industrialized countries where patients have easily access to health care (Chamontin et 
al 2001; Wolf-Maier et al 2004; Roux et al 2006). These data highlight the need for more 
effective treatment strategies, in particular of combination therapy. It is indeed clear today 
that monotherapies most often do not allow BP normalization when prescribed as initial 
treatment (Matersan et al 1995; Hansson et al 1998; Cushman et al 2002). The need for 
treatment adjustments often delays the achievement of BP control and this may inﬂuence 
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adversely the patients’ cardiovascular outcome. These concerns 
urged experts in Europe and United States of America to focus on 
the rationale and the potential usefulness of ﬁxed-dose combina-
tions for the management of hypertensive patients (Chobanian et 
al 2003; ESH-ESC 2003; Haute Autorité de Santé 2005). 
The combination containing the angiotensin-converting 
enzyme (ACE) inhibitor perindopril (Per) and the diuretic 
indapamide (Ind) has been shown to control BP in a wide range 
of patients with different degrees of hypertension as well as in 
the presence of various target organ damages and risk factors 
(Chalmers et al 2000; Mogensen et al 2003; Mourad et al 2004; 
Dahlof et al 2005). Recently, the randomized STRATHE study 
has compared 3 widely accepted antihypertensive strategies: 
a ﬁrst-line, ﬁxed-dose combination therapy, a step-by-step 
strategy, and a sequential monotherapy. The Per/Ind combi-
nation normalized BP (<140/90 mm Hg) signiﬁcantly more 
often (62%) compared with a step-by-step (47%, p = 0.005) 
and a sequential monotherapy approach (49%, p = 0.01). The 
greater efﬁcacy of the ﬁxed combination was related in par-
ticular to a higher efﬁcacy on SBP (Mourad et al 2004). The 
objective of this OPTIMAX trial was to extend the ﬁndings 
of the STRATHE study in daily medical practice.
Study protocol
Patients and methods
In this study, named OPTIMAX (OPTIMiser le tAuX de 
normalisation tensionnelle grâce à la plurithérapie de première 
intention), general practitioners and cardiologists, in hospital 
or private practice, prospectively recruited patients over a 2-
month period. In order to obtain a representative cross-section 
of patients, physicians were chosen randomly to participate in 
this study. Hypertension was deﬁned as a BP >140/90 mm Hg 
at the physician’s ofﬁce. In newly diagnosed patients as well as 
in-patients who had not been treated with any antihypertensive 
therapy for at least 3 months (“Initiation Group”), treatment was 
initiated with the ﬁxed Per/Ind combination at a 2 mg/0.625 mg 
once daily dose. The same combination was used as replacement 
therapy in patients exhibiting still high BP or having experienced 
side-effects on the previous antihypertensive therapy (“Replace-
ment Group”). The “Add-on Group” included patients who 
were treated but whose BP was only partially controlled. In this 
last group the Per/Ind combination was added to the existing 
antihypertensive treatment. Investigators were asked to enroll 
6 consecutive patients, wherever possible 2 patients in each of 
the 3 study groups. In all patients BP readings were obtained at 
inclusion in the trial and again after 3–6 months of treatment 
with the Per/Ind combination.
Patients were excluded if they were under 18 years of 
age, pregnant, or presumed not to be available for follow-up 
during at least 6 months. Patients participating in another clinical 
trial were also not eligible. A detailed medical questionnaire was 
ﬁlled out by the physicians at the patient’s inclusion and after 
3–6 months of follow-up. Information was obtained on: gender, 
age, baseline blood pressure, presence of end organ damage (left 
ventricular hypertrophy [LVH], proteinuria, and/or creatininemia 
between 12 and 20 mg/L), history of cardiovascular or renal 
disease (stroke, transient ischemic attack, myocardial infarction, 
angina, coronary revascularization, cardiac insufﬁciency, periph-
eral artery disease, renal insufﬁciency), existence of additional 
cardiovascular risk factors (diabetes, smoking, increased total 
cholesterol levels [>12.9 mmol/L], low HDL-C levels [<0.28 
mmol/L], and/or increased LDL-C levels [>8.26 mmol/L]), or 
current use of antihypertensive drug(s).
The following efﬁcacy and safety data were recorded dur-
ing the course of the study: BP levels, occurrence of signiﬁcant 
adverse events (deﬁned as a cardiovascular adverse event, an 
unplanned hospitalization, death, or any other critical event), 
tolerability (estimated by the physician as very poor, poor, 
average, good, or very good). Brachial BP was measured in 
the sitting position using usual device which was in most cases 
semi-automated equipment. BP was considered normalized if 
≤ 140/90 mm Hg. 
Statistics
The primary objective was to compare the BP normalization 
rates observed in the 3 groups. In order to detect a 1%–2% 
difference in normalization rates with an anticipated 15% of 
non-valid questionnaires and 6 patients enrolled per physician, 
power calculations revealed that 20 000 patients needed to be 
enrolled by 4820 investigators. Investigators were arbitrarily 
divided into 3600 generalists, 900 private practice cardiolo-
gists, and 320 hospital cardiologists. All patients who met the 
inclusion criteria were included in the analyses.
BP normalization rates, between groups, were compared 
using two-sided tests (Mac Nemar and χ2) with an α = 5%. 
Changes in SBP and DBP between baseline and follow-up 
visits were compared between groups using ANOVA. When 
differences were signiﬁcant, groups were compared 2 by 2 
using a Bonferroni procedure. When ANOVA was invalid 
(as deﬁned by Shapiro-Wilk, Qqplot, and Bartlett tests) com-
parisons were performed using the non-parametric Kruskall 
Wallis test. When changes from baseline were signiﬁcant, 
the non-parametric Mann-Whitney test was used to compare 
the groups 2 by 2. 
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Factors contributing to BP normalization were deter-
mined using a univariate logistic regression that compared 
normalized and non-normalized patients. The tested variables 
were: gender (female vs male); age (continuous and by cat-
egory ≥65 years vs <65 years and <50 years, 50–69 years, 
70–79 years vs ≥80 years); SBP at inclusion (continuous and 
by category <120 mm Hg or ≥140 mm Hg vs 120–139 mm 
Hg); DBP at inclusion (continuous and by category <80 mm 
Hg or ≥90 mm Hg vs 80–89 mm Hg); presence vs absence 
of end organ damage; presence vs absence of history of 
cardiovascular or renal disease(s); presence vs absence of 
additional cardiovascular risk factor(s); and degree of treat-
ment tolerability (by category: very poor, poor, average, or 
good vs very good).
A signiﬁcant difference between normalized and non-normal-
ized patients (χ2 test with an α = 15%) was needed for a variable 
to be included in the multivariate analysis. The ﬁnal model was 
built using the ascendant stepwise logistic regression program 
of SAS® (Statistical Analysis System, SAS-Institute, Cary NC, 
USA). In order to describe the proﬁle of a normalized patient, odds 
ratios and 95% conﬁdence intervals were calculated for the most 
signiﬁcant variables. Data are reported as means ±SD.
Results 
The analysis included 17 938 patients. The ﬁxed combination 
Per/Ind was prescribed in 7032 subjects as initial therapy, in 
7423 subjects as replacement therapy, and in 3483 patients as 
add-on therapy. Patients were excluded from analysis if they 
did not meet age requirements (n = 4), were not hypertensive, 
or had no BP data at baseline (n = 150).
Patients were on average 62 years of age (Table 1). At 
inclusion, they had a mean SBP of 162.3±13.1 mm Hg and 
a mean DBP of 93.6±9.1 mm Hg. Most patients (78%) had 
an SBP >150 mm Hg. Overall, newly diagnosed subjects 
(Initiation Group) tended to be younger and had slightly 
higher baseline BP values than patients who were already 
on therapy at the time of inclusion (Replacement and Add-
on Groups). A signiﬁcantly greater percentage of patients in 
the Replacement Group and in the Add-on Group had target 
organ damage, history of cardiovascular or renal disease, 
and/or cardiovascular risk factors compared with patients 
in the Initiation Group (p < 0.0001) (Table 2).
Efﬁcacy
Most patients were prescribed Per 2 mg/Ind 0.625 mg alone at 
inclusion (Table 3). BP normalization was reached in 69.6% 
(Initiation Group), 67.5% (Replacement Group) and 67.4% 
(Add-on Group) of patients (Figure 1A). After treatment 
with Per/Ind, most patients had a SBP ≤140 mm Hg (70.8%, 
68.5%, and 65.5% of patients in the Initiation, Replacement, 
and Add-on Groups, respectively) and few patients retained 
a SBP >150 mm Hg (7.0%, 8.4%, and 9.6% of patients in 
the Initiation, Replacement, and Add-on groups, respec-
tively). After treatment, most patients had a DBP ≤90 mm 
Hg (93.5%, 93.9%, and 93.3% of patients in the Initiation, 
Replacement, and Add-on Groups, respectively). 
Changes from baseline in SBP and DBP were also 
evaluated (Figure 1B-C). The largest decrease in SBP was 
recorded in the Initiation Group (26.2±12.7 mm Hg). In 
the Replacement and Add-on Groups the corresponding 
decreases averaged 19.9±14.0 and 22.4±13.0 mm Hg. The 
changes from baseline in SBP were statistically signiﬁcant 
in all groups (p vs Baseline <0.0001). The differences be-
tween groups were statistically signiﬁcant (p between Groups 
<0.0001). Similarly, the decrease in DBP was the greatest in 
the Initiation Group (14.3±9.8 mm Hg) and the smallest in 
the Replacement group (10.8±9.8 mm Hg). Changes from 
baseline in DBP were statistically signiﬁcant in all groups (p 
vs Baseline <0.0001). The differences between groups were 
also statistically signiﬁcant (p between Groups <0.0001).
In the Replacement Group, when changes in SBP were 
subdivided according to the type of previous antihyperten-
sive treatment, SBP reductions of 18.5 mm Hg (vs calcium 
antagonist) to 24.9 mm Hg (vs vasodilator) were observed 
(Table 4). In the Add-on Group, additional decreases in SBP 
of 20.4 mm Hg (plus ACE inhibitor) to 28.3 mm Hg (plus 
vasodilator) were recorded. The changes in DBP in relation 
to the previous (Replacement Group) or concomitant (Add-
on Group) therapy are also shown in Table 4. 
Safety
The treatment was overall well tolerated; at the end of follow-
up, the vast majority of patients (83%) continued treatment 
with the low-dose Per/Ind combination (2 mg/0.625 mg). In 
10% of patients, the doses had to be increased to 4 mg/1.250 
mg; the Per/Ind combination was replaced by another treatment 
in 5% of patients and discontinued in another 2% of patients. In 
the Initiation and Replacement Groups, very few patients were 
given an additional antihypertensive treatment (2%–4%).
Predictors of blood pressure  
normalization
After univariate analysis, age, baseline SBP, baseline DBP, 
LVH, proteinuria/creatinuria, angina, renal insufﬁciency, 
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peripheral artery disease, type 1 and 2 diabetes, total 
cholesterol, LDL-C, treatment, and treatment tolerance were 
selected to be included in a multivariate stepwise regression 
(data not shown). Results of the multivariate analysis revealed 
that patients over the age of 80, with high SBP at inclusion, 
with LVH, peripheral artery disease, or high total cholesterol 
levels were signiﬁcantly less likely to normalize their BP after 
treatment than patients under 70 years of age, with low SBP 
at inclusion, no LVH, no peripheral artery disease, or normal 
total cholesterol levels, respectively (Figure 2). Patients in 
whom tolerance was good or very good (Figure 2) had a 
probability of normalizing their BP 3 and 5 times greater, 
Table 1 Baseline characteristics of the patients
   Initiation Replacement Add-on Total 
   n = 7032 n = 7423 n = 3483 n = 17938
Agea in years, mean ± SD 58.2 ± 11.2 63.1 ± 11.2 65.2 ± 10.7 61.6 ± 11.5 
Genderb, % male 56.9 51.0 54.8 54.0
Previous antihypertensive treatment, %   
 Diuretic - 27.3 21.9 25.6
 Beta-blocker - 21.0 47.3 29.4
 Calcium inhibitor - 27.9 48.6 34.5
 ACE inhibitor - 25.2 14.4 21.8
 ATII inhibitor - 13.7 8.3 11.9
 Central acting - 7.1 14.7 9.5
 Other Vasodilators - 1.9 3.2 2.3
SBPb in mm Hg
 Mean ± SD 165.2 ± 11.9 159.4 ± 14.0 162.8 ± 12.2 162.3 ± 13.1
Severityb
 ≤140 mm Hg, % 1.0 10.1 1.2 4.8
 >150 mm Hg, % 86.9 69.2 79.6 78.1
DBPb in mm Hg
 mean±SD 95.6 ± 8.7 91.9 ± 9.2 93.2 ± 9.0 93.6 ± 9.1
DBPb ≤ 90 mm Hg, % 35.4 52.8 47.8 45.0
aData were missing in <3% of patients.  
bData were missing in <1% of patients.  
Abbreviations:  ACE, angiotensin converting enzyme; ATII, angiotensin-receptor II; DBP, diastolic blood pressure; SBP, systolic blood pressure.
Table 2 Target organ damage, history of cardiovascular or renal disease and cardiovascular risk factors at inclusion
Risk factor, % Initiation Replacement Add-on Total 
 n = 7032 n = 7423 n = 3483 n = 17938
Left ventricular hypertrophy 8.7 21.9 36.4 19.6
Proteinuria  4.0 8.4 15.6 8.1
Ischemic stroke 1.3 3.0 4.5 2.6
Hemorrhagic stroke  0.1 0.3 0.8 0.3
Transient ischemic attack 2.9 5.7 8.8 5.2
Myocardial infarction 0.6 3.3 8.2 3.2
Angina 2.5 7.9 17.7 7.7
Coronary revascularization 0.8 3.2 8.3 3.2
Cardiac failure 1.0 3.9 7.0 3.3
Peripheral artery disease 4.1 8.0 12.7 7.4
Renal failure 1.0 3.0 5.9 2.8
Diabetes type 1 2.9 3.8 4.7 3.6
Diabetes type 2 11.3 16.4 22.4 15.6
Smoking 38.7 28.6 27.4 32.3
Total cholesterol out of range 12.1 12.9 15.0 13.0
HDL-C out of range 2.5 2.7 3.1 2.7
LDL-C out of range 14.9 17.6 20.2 17.1
Abbreviations: CVA, cerebrovascular accident; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol.
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Figure 1 Blood pressure after 3–6 months of treatment with the ﬁxed perindopril/in-
dapamide (Per/Ind) combination. Per/Ind was initiated in newly diagnosed hypertensive 
patients (Initiation Group, n = 7032), replaced previous treatment in patients whose 
blood pressure (BP) was uncontrolled at inclusion and/or who experienced side-ef-
fects (Replacement Group, N = 7,423), or added to previous treatment in patients 
who were treated but only partially controlled (Add-on Group, n = 3483). Panel A: 
BP normalization was deﬁned as a systolic BP ≤140 mm Hg and a diastolic BP ≤90 
mm Hg. Panel B: Changes in SBP; Panel C: Changes in DBP. Data were missing in 1% 
of patients in each group. 
respectively, than those who tolerated treatment very poorly. 
Interestingly, the presence of type 2 diabetes mellitus had 
no inﬂuence on the rate of BP normalization in response to 
the Per/Ind treatment.
Discussion
Hypertension guidelines have been adapted to emphasize the 
role of combination treatments for more effective blood pres-
sure control in current medical practice (Chobanian et al 2003; 
ESH-ESC 2003). The value of this therapeutic strategy has been 
tested recently using the combination containing perindopril 
and indapamide. In a randomized controlled trial performed 
in France (STRATHE trial), 62% of hypertensive patients had 
their BP normalized (<140/90 mm Hg) after 6–9 months of Per/
Ind treatment (Mourad et al 2004). A signiﬁcantly smaller per-
centage of patients allocated to conventional strategies reached 
the target BP. Such strategies included the sequential mono-
therapy (BP normalization rate = 49%) and the step-by-step (BP 
normalization rate = 47%) approaches. A major ﬁnding of this 
study was that the Per/Ind-based strategy allowed BP normali-
zation in about twice as many patients as expected (33%) from a 
recent epidemiological study performed in France (Chamontin 
et al 2001). A high BP normalization rate (51%) has also 
been recently obtained with the Per/Ind combination in a 
large observational study (PRIMUS Study) (Holzgreve 
et al 2006).
The present study was planned to assess whether the 
BP control achieved using the Per/Ind combination in the 
STRATHE and PRIMUS studies can also be reached us-
ing the same preparation in a real-life setting. The Per/Ind 
combination reduced BP to ≤140/90 mm Hg in more than 
two thirds of patients, whether they were previously treated 
or not. This high BP control rate is equal to that observed 
in large interventional trials in which it was mandatory to 
adjust various drug regimens until BP normalization (ALL-
HAT 2003; Julius et al 2004). Notably, in these morbid-
ity–mortality trials, combination therapy was also required 
in most patients to reach both the systolic and the diastolic 
BP targets. The recognition of the need for combination 
therapy in hypertensive patients led experts in Europe and 
the USA to consider combination therapy in their guidelines 
(Chobanian et al 2003; ESH-ESC 2003; Haute Autorité de 
Santé 2005). Co-administering two drugs lowering BP by 
different mechanisms may have advantages: enhancement of 
antihypertensive efﬁcacy, and improved tolerability.
This study observed a high BP normalization rate in 
patients included in the Add-on Group. These patients were 
older, at higher cardiovascular risk and had already more 
evidence of target organ damage than patients included in the 
Initial and in the Replacement Groups. Recent surveys have 
shown that it becomes more and more difﬁcult to control BP 
as the global cardiovascular risk increases (Amar et al 2002; 
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Mancia et al 2004). This study noted the ability of Per/Ind to 
normalize BP in such hypertensive patients, even when they 
were prone to be treatment-resistant. Moreover, the Per/Ind 
combination can be prescribed with other classes of BP-low-
ering drugs, especially calcium antagonists and β-blockers.
In this study the Per/Ind combination normalized systolic 
BP, which is known to be more difﬁcult to control than di-
astolic BP. This was conﬁrmed by the results of a subanalysis 
of the STRATHE study: diastolic BP was <90 mm Hg in 
nearly all patients in whom systolic BP could be brought 
<140 mm Hg (Waeber and Mourad 2006). An improved 
control of systolic BP compared with monotherapies (the 
Table 3 Antihypertensive drug regimen at inclusion
 Initiation Replacement Add-on Total 
 n = 7032 n = 7423 n = 3483 n = 17938
Per/Ind alone, n (%) 6857 (97.5) 6588 (88.8) - 13445 (75.0)
Per/Ind + 1 additional drug, n (%) 81 (1.2) 583 (7.9) 2603 (74.2) 3267 (18.2)
Per/Ind + ≥2 additional drugs, n (%) 94 (1.3) 252 (3.4) 880 (25.3) 1226 (6.8)
Abbreviations: Per/Ind, perindopril/indapamide combination. 
Figure 2 Multivaritate analysis of factors affecting the normalization of blood pressure. Odds ratios and 95% conﬁdence intervals are presented.  
Abbreviations: DBP, diastolic blood pressure; LDL-C, low density lipoprotein-cholesterol; LVH, left ventricular hypertrophy; SBP, systolic blood pressure; Tot-C, total 
cholesterol. 
β-blocker atenolol and the ACE inhibitor enalapril) has also 
been obtained with the Per/Ind combination in hypertensive 
patients with left ventricular hypertrophy or with type 2 
diabetes mellitus (Mogensen et al 2003; de Luca et al 2004; 
Dahlof et al 2005). 
The effect of the Per/Ind combination on systolic BP may 
be related to beneﬁcial structural and functional changes of 
the vasculature, both on large arteries and microcirculation. 
The Per/Ind combination was shown to reduce central systolic 
BP more effectively than brachial systolic BP (Asmar et al 
2001). As Per/Ind slows pulse wave velocity and decreases 
the aortic augmentation index, it reﬂects changes in arterial 
0.1 1 10 100
Favors normalization
Age, < 50 vs  80 years
Age, [50 ; 70 vs  80 years
Age, [70 ; 80 vs  80 years
SBP at inclusion, high vs low
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Peripheral arterial disease, n vs y
Type 2 diabetes, n vs y
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Tolerance, very good vs very poor
[
[
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stiffness and wave reﬂections issued from arteriolar territory 
where Per/Ind is known to improve vessel wall structure 
(Asmar et al 2001; London et al 2004). Notably, in the CAFE 
trial (an ancillary study of the ASCOT trial), central aortic 
systolic BP was substantially lower during the amlodipine/
perindopril treatment than during the atenolol/thiazide 
treatment. This differential response of central BP appears 
clinically relevant as it might have played a determinant 
role in the better protection against stroke afforded by the 
amlodipine/perindopril compared with the atenolol/thiazide 
drug regimen (Williams et al 2006). 
The presence of diabetes in patients treated with the Per/
Ind combination was of interest as this combination has been 
previously shown to have beneﬁcial effects on albuminuria 
and cardiovascular events in hypertensive patients with type 
2 diabetes (Mogensen et al 2003). These data are consistent 
with the current understanding of the direct action of ACE 
inhibitors on the renin-angiotensin system. Not only do ACE 
inhibitors improve renal and cardiovascular outcomes in 
diabetic patients, but these effects have been shown to extend 
beyond those attributable to blood pressure control and may 
be linked to an increase in tissue perfusion (Heart Outcomes 
Prevention Evaluation Study Investigators 2000; Mourad et 
al 2003; Renauld et al 2004; Kawata et al 2006). The use of 
the Per/Ind combination in diabetic patients is being further 
investigated in the ADVANCE study, which will evaluate the 
impact of tight glucose control and changes in blood pressure 
through combination treatment (Per/Ind and a modiﬁed-re-
lease formulation of gliclazide) on both macrovascular and 
microvascular endpoints (ADVANCE 2001).
The results of the present trial should be interpreted with 
caution as the study protocol was adapted to be meaningful 
in everyday practice. Because of the large sample size this 
study demonstrated that hypertension can be successfully 
controlled in most patients with various risk factors, co-
morbidities and degrees of BP elevation. These results could 
assist physicians in the management of blood pressure control 
in general practice.
Conclusion
An antihypertensive strategy based on the ﬁrst-line Per/Ind 
combination, administered as initial, replacement, or add-on 
therapy, achieved the desired BP normalization rates. These 
exceeded those observed in clinical studies in a broad range 
of patients with various added risk factors and treatments, in-
cluding the elderly, diabetic, or with target organ damage.
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Central AH 234a –21.3 ± 13.7 –11.6 ± 8.8 75 –22.4 ± 11.4 –11.7 ± 8.1
Vasodilator 60 –24.9 ± 14.4 –12.9 ± 10.1 25 –28.3 ± 10.5 –15.3 ± 6.4
aSBP data missing for 1 patient 
bDBP data missing for 1–4 patients.  
Abbreviations: ACE, angiotensin converting enzyme; AH, antihypertensive; ATII, angiotensin-receptor II; DBP, diastolic blood pressure; SBP, systolic blood pressure; tt, 
treatment.
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